Medeon Biodesign, Inc. Statistics
Medeon Biodesign, Inc. (6499) Stock Statistics & Valuation Metrics
Total Valuation
Medeon Biodesign, Inc. has a market cap or net worth of TWD 6.85B. The enterprise value is TWD 6.07B.
- Market Cap
- TWD 6.85B
- Enterprise Value
- TWD 6.07B
Share Statistics
Medeon Biodesign, Inc. has 96,944,890 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 96,944,890
- Owned by Insiders
- ―
- Owned by Institutions
- ―
Financial Efficiency
Medeon Biodesign, Inc.’s return on equity (ROE) is -0.45 and return on invested capital (ROIC) is -43.50%.
- Return on Equity (ROE)
- -0.45
- Return on Assets (ROA)
- -0.38
- Return on Invested Capital (ROIC)
- -43.50%
- Return on Capital Employed (ROCE)
- -0.45
- Revenue Per Employee
- 280.36K
- Profits Per Employee
- -446.57K
- Employee Count
- 1,496
- Asset Turnover
- 0.24
- Inventory Turnover
- 14.52
Valuation Ratios
The current PE Ratio of Medeon Biodesign, Inc. is -10.47. Medeon Biodesign, Inc.’s PEG ratio is -1.00.
- PE Ratio
- -10.47
- PS Ratio
- 16.99
- PB Ratio
- 3.00
- Price to FCF
- -13.96
- Price to Operating Cash Flow
- -7.20
- PEG Ratio
- -1.00
Income Statement
In the last 12 months, Medeon Biodesign, Inc. had revenue of 419.43M and earned -668.06M in profits. Earnings per share was -7.24.
- Revenue
- 419.43M
- Gross Profit
- 58.83M
- Operating Income
- -722.51M
- Pretax Income
- -719.69M
- Net Income
- -668.06M
- EBITDA
- -615.15M
- Earnings Per Share (EPS)
- -7.24
Cash Flow
In the last 12 months, operating cash flow was -511.73M and capital expenditures -9.10M, giving a free cash flow of -520.83M billion.
- Operating Cash Flow
- -511.73M
- Free Cash Flow
- -520.83M
- Free Cash Flow per Share
- -10.60
Dividends & Yields
Medeon Biodesign, Inc. pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -7.36%
- Earnings Yield
- -16.06%
Stock Price Statistics
- Beta
- 0.48
- 52-Week Price Change
- -29.45%
- 50-Day Moving Average
- 76.03
- 200-Day Moving Average
- 79.60
- Relative Strength Index (RSI)
- 37.70
- Average Volume (3m)
- 368.13K
Important Dates
Medeon Biodesign, Inc. upcoming earnings date is Mar 04, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Oct 29, 2026
- Next Earnings Date
- Mar 04, 2027
- Ex-Dividend Date
- ―
Financial Position
Medeon Biodesign, Inc. as a current ratio of 8.21, with Debt / Equity ratio of 7.66%
- Current Ratio
- 8.21
- Quick Ratio
- 8.06
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 0.66
- Interest Coverage Ratio
- -196.23
Taxes
In the past 12 months, Medeon Biodesign, Inc. has paid -352.00K in taxes.
- Income Tax
- -352.00K
- Effective Tax Rate
- 0.00
Enterprise Valuation
Medeon Biodesign, Inc. EV to EBITDA ratio is -12.54, with an EV/FCF ratio of -13.01.
- EV to Sales
- 15.83
- EV to EBITDA
- -12.54
- EV to Free Cash Flow
- -13.01
- EV to Operating Cash Flow
- -13.24
Balance Sheet
Medeon Biodesign, Inc. has TWD 959.51M in cash and marketable securities with TWD 151.49M in debt, giving a net cash position of TWD 808.02M billion.
- Cash & Marketable Securities
- TWD 959.51M
- Total Debt
- TWD 151.49M
- Net Cash
- TWD 808.02M
- Net Cash Per Share
- TWD 8.33
- Tangible Book Value Per Share
- TWD 22.84
Margins
Gross margin is 9.16%, with operating margin of -144.72%, and net profit margin of -134.54%.
- Gross Margin
- 9.16%
- Operating Margin
- -144.72%
- Pretax Margin
- -143.55%
- Net Profit Margin
- -134.54%
- EBITDA Margin
- -126.22%
- EBIT Margin
- -144.13%
Analyst Forecast
The average price target for Medeon Biodesign, Inc. is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- 69.62%
- EPS Growth Forecast
- 59.41%
